Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report on a case of cutaneous lymphomatoid granulomatosis underscores the pivotal role dermatologists have in its early diagnosis, which could potentially improve the otherwise poor prognosis.

Endoxan often causes hair loss, which usually starts in the third week of treatment.

This study found that inhibiting EGFR signaling in mice can prevent alopecia caused by cyclophosphamide treatment, highlighting its potential role in managing chemotherapy-induced hair loss.

This study suggests that pretreatment with a PPAR-γ modulator may prevent damage to hair follicle stem cells caused by a chemotherapy metabolite, potentially offering a strategy to mitigate permanent chemotherapy-induced alopecia.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

This case report describes the successful treatment of severe bullous erythema multiforme in a patient using cyclosporine, where prior high-dose corticosteroids had only partially worked.

This case report discusses an instance of cystitis caused by the chemotherapy drug Cytoxan, with no new findings reported.

This study observed that class IV diffuse proliferative glomerulonephritis was the most common form of lupus nephritis among the children studied, with remission achieved in a significant portion after treatment.

This study reports that chemotherapy-induced alopecia in mice may be linked to decreased laminin-511 and increased laminin-332 around hair follicles, suggesting a potential mechanism for abrupt hair loss.

Vitamin D3 may prevent hair loss from chemotherapy, but side effects and cancer cell protection are concerns.

This study found that M30 may protect against cyclophosphamide-induced alopecia in mice by enhancing hair growth and preventing abnormal hair, suggesting its potential as a treatment.

This study found that transient inhibition of eIF4E in a transgenic mouse model protected against cyclophosphamide-induced hair loss by inducing cell cycle arrest and reducing cellular apoptosis.

This article discusses the roles of pediatrics and dermatology departments at Yale University School of Medicine, but reports no specific clinical results.

This case study reports that ciclosporin effectively managed symptoms in a patient with steroid-dependent sudden sensorineural hearing loss, allowing discontinuation of corticosteroids and confirming remission through audiometry.

In this study using a mouse model, researchers found that DNA methylation of the miR-365-1 promoter plays a role in reducing apoptosis in hair follicle stem cells during chemotherapeutic alopecia.

This review discusses the impact of oncological therapy on hair loss, highlighting that while most alopecia is reversible, it can be permanent depending on treatment type and factors.

In this study, researchers found that cyclophosphamide treatment unexpectedly reduced splenic melanin deposition in a murine model, whereas this effect was down-regulated more by the normal and dystrophic catagen phase of the hair cycle.

This study found that human scalp hair follicles transplanted onto chemotherapy-treated immunodeficient mice closely mimic chemotherapy-induced hair loss seen in cancer patients, providing a valuable model for research.

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

This case study reported the successful management of cardiac tamponade in a pregnant woman with systemic lupus erythematosus using pericardiocentesis and immunosuppressant therapy, although the patient declined cyclophosphamide treatment.

This study found that age is the most significant risk factor for hemorrhagic cystitis after hematopoietic stem-cell transplantation, with additional risk factors including cyclophosphamide-based prophylaxis and, among male recipients, prostatic hyperplasia.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.

This case report documents two instances of red-haired men with patch-type alopecia areata, where hair regrowth occurred in black rather than red, an unusual phenomenon potentially linked to pigmentation and receptor pathways.

This study observed that topical prostaglandin treatments may protect against hair follicle injury during chemotherapy, as indicated by preserved eyelashes in patients using these treatments.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

This study suggests that human placenta treatment may promote hair regrowth in chemotherapy-induced alopecia by inhibiting apoptosis and encouraging hair follicle proliferation in a mouse model.

This report describes three cases of hypertrichosis lanuginosa acquisita occurring after cytotoxic chemotherapy for cancer, suggesting a possible relationship which is discussed alongside a review of existing literature.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This case report found that a patient with cutaneous polyarteritis nodosa experienced rare and severe manifestations, including digital gangrene and a breast ulcer, requiring aggressive treatment and resulting in below-knee amputation.

A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.